Gene And Cell Therapies Targeting CNS Disorders Market Continues To Grow with Increasing Adoption Of Strategic Collaborations By The Market Players
Central nervous system (CNS) disorders are the conditions that affect the brain, the spinal cord, and the quality of life. Common examples of central nervous system (CNS) diseases include bipolar disorder, depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, and migraine. Gene and cell therapies are a growing field of medical research. The idea is to use the genetic material in an individual’s body to treat a disease or condition. Cell therapy for CNS diseases has developed to new levels of clinical applications. There are several clinical studies that are investigating gene and cell therapies for various CNS disorders.
˜”*°•.˜”*°• 𝐂𝐡𝐫𝐢𝐬𝐭𝐦𝐚𝐬 𝐒𝐚𝐥𝐞 𝐢𝐬 𝐋𝐢𝐯𝐞 •°*”˜.•°*”˜
𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐨 𝐀𝐯𝐚𝐢𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐅𝐫𝐨𝐦 𝟐𝟓-𝟑𝟎% 𝐭𝐢𝐥𝐥 𝟑𝟏-𝐃𝐞𝐜-𝟐𝟎𝟐𝟏
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/4705
Increasing adoption of inorganic strategies such as collaborations by market players to develop gene editing therapies is expected to propel growth of the global gene and cell therapies targeting CNS disorders market during the forecast period. For instance, in November 2021, Moderna Inc., a biotech company collaborated with Metagenomi, Inc. for research and development of new gene editing systems for application in in-vivo human therapeutic. Under this collaboration, the companies will use new gene editing tools of Metagenomi and control mRNA platform of Moderna, and lipid nanoparticle (LNP) delivery technologies to develop therapies for patients with severe genetic disorders.
However, high operational cost of gene and cell therapies is expected to hamper growth of the global gene and cell therapies targeting CNS disorders market during the forecast period.
Impact of COVID-19:
The outbreak of the COVID-19 pandemic had a significant impact on growth of the global gene and cell therapies targeting CNS disorders market. Several countries adopted strict lockdown policies, in order to control the spread of the COVID-19 virus, due to which several clinical trials were all over the world were disrupted as the patient enrolments were suspended. However, relaxation in the COVID-19 restrictions and decreasing cases is expected to support growth of the global gene and cell therapies targeting CNS disorders market.
To Get a Free Research PDF Brochure Here @ https://www.coherentmarketinsights.com/insight/request-pdf/4705
- The global gene and cell therapies targeting CNS disorders market is expected to expand, due to increasing licensing and inventory agreements, and collaborations in market players for development of gene therapies. For instance, in October 2021, Voyager Therapeutics entered into license option agreement with Pfizer for next generation TRACER AAV capsid for enabling neurologic and cardiovascular gene therapy programs.
- Among regions, North America is expected to witness significant growth in the global gene and cell therapies targeting CNS disorders market during the forecast period due to rising approval and lunch of products in the region.
- Kay players active in the global gene and cell therapies targeting CNS disorders market are BrainStorm Cell Therapeutics, UniQure Biopharma, Novartis, Brain Neurotherapy Bio (AskBio), Corestem, NeuroGeneration, Q Therapeutics, Eli Lilly and Company, Helixmith, Sio Gene Therapies, Rapa Therapeutics, Longeveron, Neuroplast, Hoffmann-La Roche, StemCyte, Sangamo Therapeutics, Ferrer Internacional, Libella Gene Therapeutics, Neuralstem, Stemedica Cell Technologies, and Ferrer Internacional.
To Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/4705
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027